Brought to you by 
Sorin gets European rights to Respicardia's sleep apnea device, plus option to buy company; deal later terminated
27 Apr 2021
Executive Summary
Cardiovascular device firm Sorin Group SPA acquired exclusive rights to distribute Respicardia Inc.’s (implantable therapies to improve respiratory and cardiovascular health) remede neurostimulation system for central sleep apnea (CSA) in select European countries for five years.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sorin gets European rights to Respicardia's sleep apnea device, plus option to buy company; deal later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice